EuroEspes S.A. Competitors

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 59 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,700 employees, Biocodex generated net revenues of above €500million in 2023, including 1/3 in France and 2/3 internationally. The group is present in more than 100 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide. To report quality complaint(s) or adverse event(s) related to Biocodex products please visit https://www.biocoreport.com/en/

Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them. Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network. Almirall is listed on the Spanish Stock Exchange (ticker: ALM).